Vaidya Rakhee, Pruthi Rajiv, Thompson Carrie
Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Blood Coagul Fibrinolysis. 2014 Mar;25(2):188-90. doi: 10.1097/MBC.0000000000000016.
Heparin-induced thrombocytopenia type 2 is an immune-mediated phenomenon associated with heparin exposure that has the potential to evolve into life-threatening thrombosis if not recognized and treated early. Lack of immediate availability of a confirmatory assay often leaves the diagnosis to the clinician's discretion. Despite a high negative predictive value, the clinical '4Ts' scoring system carries a small but a real risk of missing the diagnosis, especially with atypical presentations. We describe one such case of rapid-onset, heparin-induced thrombocytopenia with thrombosis that developed in the setting of catheter-directed ablation of atrial fibrillation, several months after a brief exposure to low-molecular-weight heparin. The clinical scenario as well as the risk of progressing to catastrophic complications prompted immediate discontinuation of all heparin products and treatment with a direct thrombin inhibitor, despite a low pretest clinical score.
2型肝素诱导的血小板减少症是一种与肝素暴露相关的免疫介导现象,如果不及早识别和治疗,有可能演变成危及生命的血栓形成。由于缺乏即时可用的确诊检测方法,诊断往往由临床医生自行决定。尽管临床“4Ts”评分系统具有较高的阴性预测价值,但仍存在较小但实际的漏诊风险,尤其是对于非典型表现。我们描述了这样一例在房颤导管消融术后,短暂接触低分子肝素数月后迅速发生的肝素诱导的血小板减少症并伴有血栓形成的病例。尽管预检临床评分较低,但临床情况以及进展为灾难性并发症的风险促使立即停用所有肝素产品并使用直接凝血酶抑制剂进行治疗。